GluN2A Mediates PS-Induced Depressive-Like Behavior by Activating CaMKII and Inhibiting Myelinization
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2812347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Huimei Huang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Calcium-Calmodulin-Dependent Protein Kinase Type 2, Prenatal Exposure Delayed Effects, Receptors, N-Methyl-D-Aspartate, Depression. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Basic Research Plan in Shaanxi Province of China, Shaanxi Province key research and development plan general project in the field of social development.
Abstract (Originalsprache)
Background
Prenatal stress (PS) can induce depression in offspring, but the underlying mechanisms are still unknown.
Objective
The aim of this work was to investigate the mechanism that underlies PS-induced depressive-like behavior in offspring.
Methods
A prenatal restraint stress procedure was developed in which pregnant rats at GD14 to GD20 were placed head-first into a well-ventilated bottle three times each day and for 45 min each time. Depressive-like behavior in the male offspring was examined using the sucrose preference test (SPT) and the forced swim test (FST). The level of glutamate and the expression levels of GluN2A, p-CaMKII and myelin basic protein (MBP) in the hippocampus of PS-susceptible (PS-S) offspring were also evaluated. To clarify the mechanism by which PS leads to depression in offspring, the effects of excessive corticosterone were also investigated using an in vitro “injured neuronal” model.
Results
The glutamate level in the hippocampus of PS-S male offspring was significantly elevated compared to controls. The expression levels of GluN2A and p-CaMKII were also altered. In addition, the optical density of MBP staining and the expression levels of MBP mRNA and MBP protein were decreased, demonstrating impaired myelinization in the hippocampus. Treatment of PS-S offspring with the GluN2A receptor antagonist NVP-AAM077 resulted in antidepressant-like effects in the FST, as well as rescue of the MBP and p-CaMKII abnormalities.
Conclusions
These findings indicate that GluN2A is a promising target in the development of pharmacotherapies for PS-induced depression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Department of Blood Purification, The First Affiliated Hospital of Xi'an Jiaotong University, 710061 Xi'an, Shaanxi, China.
- Department of Nephrology, Xi'an Children's Hospital (The Affiliated Children's Hospital of Xi'an Jiaotong University), 710003 Xi'an, Shaanxi, China.
- Shaanxi Institute for Pediatric Diseases, Xi'an Key Laboratory of Children's Health and Diseases, Xi'an Children's Hospital (The Affiliated Children's Hospital of Xi'an Jiaotong University), 710003 Xi'an, Shaanxi, China.
Förderung
- Natural Science Basic Research Plan in Shaanxi Province of China
- Shaanxi Province key research and development plan general project in the field of social development
Zitieren
APA
Huang, H., Jiang, H., & Sun, H. (2023). GluN2A Mediates PS-Induced Depressive-Like Behavior by Activating CaMKII and Inhibiting Myelinization. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2812347
Vancouver
Huang H, Jiang H, Sun H. GluN2A Mediates PS-Induced Depressive-Like Behavior by Activating CaMKII and Inhibiting Myelinization. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2812347
BibTeX
@article{Huang2023,
author = {Huang, Huimei and Jiang, Hongli and Sun, Hongli},
title = {GluN2A Mediates PS-Induced Depressive-Like Behavior by Activating CaMKII and Inhibiting Myelinization},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2812347}
}
EUVIMED